27 December 2022 in Journal of Thrombosis and Haemostasis
THthe International Society on Thrombosis and Haemostasis
the International Society on Thrombosis and Haemostasis
+3
11 May 2020 in Journal of the American Geriatrics Society
21 February 2022 in Thrombosis and Haemostasis
Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)—the combination of low-dose anticoagulants with antiplatelet agents—to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens—mostly rivaroxaban and aspirin—in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis—and thus maximize safety—should be assessed in appropriate populations.
3 February 2026 in Journal of Thrombosis and Haemostasis
28 August 2026 in Bleeding, Thrombosis and Vascular Biology
Despite a narrow therapeutic range, need for frequent monitoring, and continuous dosing adjustment, vitamin K antagonists like warfarin remain widely prescribed worldwide owing to superiority over newer anticoagulants in key patient populations and low cost. Several models exist to guide warfarin dosing in stable outpatients, but none validated for inpatient warfarin dosing. Instead, clinicians use blanket pre-specified warfarin initiation strategies, and adjust the dose based on clinical gestalt. There is a need for warfarin dosing guidance during the inpatient period to improve time to achieve the therapeutic effect, potentially decrease adverse events related to over- or under-anticoagulation, and reduce hospitalization times. Warfarin response is characterized by inter-individual and inter-temporal variability. At the same time, modern electronic health record infrastructure has made relevant data easily accessible. A simplified pharmacokinetic/pharmacodynamic (PK/PD) model for inpatient warfarin dosing has been previously described, but no implementation has been disseminated. This methods paper is intended to introduce a stepwise derivation and an open-source implementation of this previously described simplified PK/PD model designed for warfarin dosing in the inpatient setting that can be used for subsequent large-scale validation. The model has the potential, after extensive validation and extension, to serve as the core of a clinical decision support system that can accurately provide dosing recommendations to clinicians.